TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial - TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial (TAS-CC3 study)

Teikyo University Chiba Medical Center0 个研究点目标入组 31 人开始时间: 2016年8月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)contraindications for TAS-102 and BEvacizumab 2)previously received chemotherapy with TAS-102 3)severe drug allergy 4)pregnant woman or Possibility of the pregnant woman. male patient who hoping partner's pregnancy. 5)patient who has important clinical complications(symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 6)other active malignancies 7)have pleural effusion and ascitic fluid with the treatment 8)Comorbidity or history of heart failure 9)gastrointestinal ulcer or bleeding 10)previous hemoptysis 11)Peritoneal metastases at image 12)Clinical or radiological evidence of CNS metastases 13)Current or previous (within the last 6 months) history of GI perforation 14)Patient with interstitial pneumonia or lung fibrosis confirmed in imaging study 15)ongoing treatment with anticoagulant 16)Synchronous or metachronous multiple malignancy within the last 5 year disease free interval 17)Under coutinuous steroid administration 18)dicision of unsuitable for this study by the investigator

发起方